RealTime Dynamix™: Psoriasis US Q1
The Psoriasis market continues to grow, driven by a growing treatment population and the continued uptake of biologics and advanced therapies. In particular, the IL-17 class shows rapid growth, with both Cosentyx (Novartis) and 2016 launched Taltz from Eli Lilly. Tracking the interplay of these two highly regarded treatments will be central to the 2017 […]
Will US Rheumatologists Follow in the Footsteps of Dermatologists for Adoption of Eli Lilly’s Taltz?
CAMBRIDGE, Mass., Jan. 26, 2017 /PRNewswire/ — A recent study of 100 surveyed US rheumatologists, reveals that after viewing a product profile for the likely second to market IL-17 inhibitor for PsA, 84% anticipate prescribing Lilly’s Taltz (ixekizumab), if approved. Furthermore, the vast majority of rheumatologists plan to initiate treatment within the first-year of launch. […]
Eli Lilly’s Taltz Gaining Ground in Psoriasis Market, Leaving Novartis’ Cosentyx at Risk in 2017, according to Spherix Global Insights
Though Cosentyx significantly leads the PsO market in biologic patient share and satisfaction; over 100 surveyed US dermatologists’ projected share at six months out reveals the two IL-17 inhibitors as neck and neck. Download Report Overview CAMBRIDGE, Mass., Nov. 29, 2016 /PRNewswire/ — At just over six months post launch, US dermatologists report a significant […]
RealTime Dynamix™: Psoriasis
RealTime Dynamix: Psoriasis Q2 is the baseline first report in a three-part 2016 series focusing on current and anticipated future trends in the PsO market. Report content includes current and future patient share, treatment satisfaction, industry contact rates, awareness and familiarity with products in development, sources of information about development compounds, statement agreements, line of […]
Eli Lilly’s Taltz And Novartis’ Cosentyx Introduce Disruption To The Psoriasis Market, According To A New Report From Spherix Global Insights
As the two IL-17s fight for differentiation, other biologics brace for share offsets, based on a recent survey of 99 US dermatologists. Download Report Overview ZUG, Switzerland, Sept. 19, 2016 — Over 70% of the surveyed dermatologists report that their biologic use has increased over the past year, playing catch up to rheumatologists’ use in […]
A Waltz with Taltz – Dermatologists Report Early Adoption of Ixekizumab in Psoriasis
Download Report Overview At just over one month post launch, one-third of dermatologists report having prescribed Eli Lilly’s IL-17 inhibitor, Taltz, according to a recent report from Spherix Global Insights. July 26, 2016 – Cambridge, Massachusetts. At approximately six weeks after launch of Eli Lilly’s Taltz, one-third of surveyed dermatologists (n=99) report trialling the latest […]
